Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Biotech, Berkshire Medical Center Collaborate on Prostate, Breast Cancer Biomarker Identification

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today announced a research and collaboration agreement with Berkshire Medical Center aimed at prostate cancer and breast cancer biomarker identification.

As part of the deal, Berkshire — the primary affiliate of Berkshire Health Systems — will provide Nuclea with samples of serum and tumor tissue for the identification of biomarkers for cancer diagnostics, with patient consent. Pittsfield, Mass.-based Nuclea develops genetic, protein, and antibody biomarkers and diagnostic assays to help determine which therapeutics may be most appropriate for individual patients.

Last month, it said it raised $4.2 million of a targeted $5 million in a Series D round.

Financial and other terms of the today's deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.